Neuren well funded for clinical trials
05 March, 2014 by Dylan Bushell-EmblingNeuren's (ASX:NEU) cash balance of $25m should be enough to fund key clinical trials of neurological drug candidate NNZ-2566 through to the expected receipt of licensing revenue in 2015, Bell Potter says.
AusBiotech articulates support for tax reform
04 March, 2014Building on the strategic plan that was presented at the AusBiotech national conference in November by AusBiotech Chair Dr Deborah Rathjen, the organisation is continuing its call for further tax reform in Australia.
Mesoblast well funded for next 2-3 years
04 March, 2014 by Dylan Bushell-EmblingBell Potter Securities has maintained its 'buy' rating for Mesoblast shares - with a slightly reduced price target - on the strength of the company's 1H14 results.
New appointments at ANSTO
04 March, 2014ANSTO's CEO, Dr Adrian (Adi) Paterson, has been reappointed and businessman James McDowell has joined the ANSTO board.
Phosphagenics names new board
03 March, 2014 by Dylan Bushell-EmblingLaurence Gozlan, Nathan Drona and Dr Geert Cauwenbergh have joined Phosphagenics (ASX:POH) as non-executive directors.
Fibrotech secures patents in NA for fibrosis drugs
03 March, 2014 by Dylan Bushell-EmblingFibrotech Therapeutics has been awarded patents in the US and Canada covering its portfolio of antifibrotic drug candidates.
Calzada appoints new director, posts 1H14 results
28 February, 2014 by Dylan Bushell-EmblingCalzada (ASX:CZD) has appointed David Williams as a non-executive director and revealed it improved its cash position during 1H14.
Government announces funding for cancer and hearing CRCs in latest round
27 February, 2014In the latest announcement dedicating almost $186 million in funding, the federal government will create three new cooperative research centres (CRCs) and extend four existing CRCs, including the Hearing CRC and the Cancer Therapeutics CRC, to drive research that will deliver practical benefits.
No progress for Pharma Patents Review
26 February, 2014No plan to release the Pharmaceutical Patents Review Report, says Minister for Industry, Ian Macfarlane.
Immuron closes $9.6m rights issue
26 February, 2014 by Dylan Bushell-EmblingImmuron (ASX:IMC) has completed a $9.66m capital raising, giving it funds to commence a phase IIb trial of its liver disease drug candidate in nonalcoholic steatohepatitis (NASH).
Ellex gets CE mark for laser eye treatment
26 February, 2014 by Dylan Bushell-EmblingEllex Medical Lasers (ASX:ELX) has been granted approval to market 2RT - a laser therapy for chronic eye disease AMD - in the European Union.
Benitec to raise up to $31.5m in placement
25 February, 2014 by Dylan Bushell-EmblingBenitec Biopharma (ASX:BLT) has launched a private placement to raise up to $31.5 million to further its ddRNAi development programs.
AusBiotech members recognised in Healthcare Awards
25 February, 2014Admedus, Nanosonics, Universal Biosensors and CSL were among the companies recognised last week as Australia's best performers in the Australian healthcare industry at the 2014 Frost & Sullivan Australia Healthcare Awards.
Simavita commences trading on ASX
21 February, 2014 by Dylan Bushell-EmblingSimavita (ASX:SVA) has commenced trading on the ASX, as the company gears up for the US launch of its Smart Incontinence Management product.
Australia to put spotlight on global brain mapping initiatives
20 February, 2014Australia is to host an eminent world congress as the prominence of brain mapping is growing around the globe. Recent and significant initiatives from the US and Europe have been initiated to better understand the brain and develop new and better treatments for conditions like Alzheimer's, autism and depression, and to help people suffering from brain injuries.
